Control of cardiac valve related hemolytic anemia by sulphinpyrazone.
Sulphinpyrazone has a beneficial effect in a patient with hemolytic anemia related to cardiac valve prostheses. It may also have a clinically significant role in the control of symptoms and may delay the need for surgery.
D000743:Anemia, Hemolytic / Q000188:drug therapy* / Q000209:etiology; D001024:Aortic Valve Stenosis / Q000601:surgery; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013442:Sulfinpyrazone / Q000627:therapeutic use*
D013442:Sulfinpyrazone